CD28 and neoplasm: Although neither of these checkpoint inhibitors engage CD28 directly, their primary therapeutic mechanism is enhancement of costimulation, strongly suggesting that biologics that stimulate CD28 signaling in a tumor-targeted manner have potential as a novel class of immunotherapy.